Supernus Pharmaceuticals (SUPN) Change in Acquisitions & Divestments (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Change in Acquisitions & Divestments data on file, last reported at $59.2 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $59.2 million, down 62.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $677.5 million (up 32.13% YoY), and the FY2025 annual result was $774.5 million, up 55.25% from the prior year.
• Change in Acquisitions & Divestments improved to $59.2 million in Q1 2026 per SUPN's latest filing, from $39.3 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $468.6 million in Q3 2025 and troughed at $17.6 million in Q4 2022.
• A 5-year average of $111.4 million and a median of $75.4 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments sank 95.36% in 2022, then soared 729.88% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $17.6 million in 2022, then soared by 102.87% to $35.6 million in 2023, then jumped by 273.5% to $133.0 million in 2024, then tumbled by 70.43% to $39.3 million in 2025, then soared by 50.62% to $59.2 million in 2026.
• Business Quant data shows SUPN's Change in Acquisitions & Divestments at $59.2 million in Q1 2026, $39.3 million in Q4 2025, and $468.6 million in Q3 2025.